<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>109(2)</volume><submitter>Nakano K</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>For patients who have difficulty controlling blood glucose even with insulin administration, xenogeneic islet cells, including human stem cell-derived pancreatic islets (hSC-islet) and porcine islets, have garnered attention as potential solutions to challenges associated with donor shortages. For the development of diabetes treatment modalities that use cell transplantation therapy, it is essential to evaluate the efficacy and safety of transplanted cells using experimental animals over the long term.&lt;h4>Methods&lt;/h4>We developed permanent diabetic immune-deficient mice by introducing the Akita (C96Y) mutation into the rodent-specific Insulin1 gene of NOD/Shi-scid IL2rγc null (NOG) mice ( Ins1 C96Y/C96Y NOG). Their body weight, nonfasting blood glucose, and survival were</pubmed_abstract><journal>Transplantation</journal><pagination>e81-e91</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11745600</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A Novel Immunodeficient Hyperglycemic Mouse Carrying the Ins1 Akita Mutation for Xenogeneic Islet Cell Transplantation.</pubmed_title><pmcid>PMC11745600</pmcid><pubmed_authors>Yanobu-Takanashi R</pubmed_authors><pubmed_authors>Shimoda M</pubmed_authors><pubmed_authors>Takahashi R</pubmed_authors><pubmed_authors>Fukuda S</pubmed_authors><pubmed_authors>Sakuma T</pubmed_authors><pubmed_authors>Yamamoto T</pubmed_authors><pubmed_authors>Goto M</pubmed_authors><pubmed_authors>Nakano K</pubmed_authors><pubmed_authors>Okochi H</pubmed_authors><pubmed_authors>Yabe SG</pubmed_authors><pubmed_authors>Shimizu Y</pubmed_authors><pubmed_authors>Okamura T</pubmed_authors></additional><is_claimable>false</is_claimable><name>A Novel Immunodeficient Hyperglycemic Mouse Carrying the Ins1 Akita Mutation for Xenogeneic Islet Cell Transplantation.</name><description>&lt;h4>Background&lt;/h4>For patients who have difficulty controlling blood glucose even with insulin administration, xenogeneic islet cells, including human stem cell-derived pancreatic islets (hSC-islet) and porcine islets, have garnered attention as potential solutions to challenges associated with donor shortages. For the development of diabetes treatment modalities that use cell transplantation therapy, it is essential to evaluate the efficacy and safety of transplanted cells using experimental animals over the long term.&lt;h4>Methods&lt;/h4>We developed permanent diabetic immune-deficient mice by introducing the Akita (C96Y) mutation into the rodent-specific Insulin1 gene of NOD/Shi-scid IL2rγc null (NOG) mice ( Ins1 C96Y/C96Y NOG). Their body weight, nonfasting blood glucose, and survival were</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Feb</publication><modification>2025-04-05T09:32:35.596Z</modification><creation>2025-04-05T09:32:35.596Z</creation></dates><accession>S-EPMC11745600</accession><cross_references><pubmed>39104009</pubmed><doi>10.1097/TP.0000000000005152</doi></cross_references></HashMap>